C
CIDARA THERAPEUTICS INC
NASDAQ: CDTX (Cidara Therapeutics, Inc.)
Kemas kini terakhir: 14 jam lalu24.28
-1.42 (-5.53%)
Penutupan Terdahulu | 25.70 |
Buka | 25.85 |
Jumlah Dagangan | 162,511 |
Purata Dagangan (3B) | 154,407 |
Modal Pasaran | 314,906,752 |
Harga / Pendapatan (P/E Ke hadapan) | 5.75 |
Harga / Jualan (P/S) | 99.60 |
Harga / Buku (P/B) | 1.34 |
Julat 52 Minggu | |
Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
Margin Operasi (TTM) | -7,154.43% |
EPS Cair (TTM) | -26.82 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 2.19% |
Nisbah Semasa (MRQ) | 4.25 |
Aliran Tunai Operasi (OCF TTM) | -176.53 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.09 M |
Pulangan Atas Aset (ROA TTM) | -40.46% |
Pulangan Atas Ekuiti (ROE TTM) | -219.59% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Cidara Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.9
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -4.5 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 4.0 |
Purata | 0.88 |
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak® platform targeting oncologic, viral and autoimmune diseases. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 1.38% |
% Dimiliki oleh Institusi | 69.49% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Acuta Capital Partners, Llc | 31 Mar 2025 | 125,708 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 50.00 (Guggenheim, 105.93%) | Beli |
Median | 40.50 (66.80%) | |
Rendah | 35.00 (RBC Capital, 44.15%) | Beli |
35.00 (Needham, 44.15%) | Beli | |
35.00 (HC Wainwright & Co., 44.15%) | Beli | |
Purata | 41.33 (70.22%) | |
Jumlah | 6 Beli | |
Harga Purata @ Panggilan | 23.01 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Needham | 23 May 2025 | 35.00 (44.15%) | Beli | 24.28 |
10 Apr 2025 | 35.00 (44.15%) | Beli | 17.09 | |
RBC Capital | 23 May 2025 | 35.00 (44.15%) | Beli | 24.28 |
Guggenheim | 16 May 2025 | 50.00 (105.93%) | Beli | 25.50 |
09 May 2025 | 35.00 (44.15%) | Beli | 18.63 | |
JMP Securities | 09 May 2025 | 47.00 (93.57%) | Beli | 18.63 |
29 Apr 2025 | 46.00 (89.46%) | Beli | 21.12 | |
Citizens Capital Markets | 12 Mar 2025 | 46.00 (89.46%) | Beli | 23.00 |
HC Wainwright & Co. | 10 Mar 2025 | 35.00 (44.15%) | Beli | 22.39 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |